Sanyou Biopharmaceuticals is a CRO company featuring phage display antibody libraries of trillion capacity and offering integrated solutions for innovative antibody drugs that include antibody discovery, efficacy validations and CMC. Currently, the company has 240+ employees, R&D laboratories of 11000 m2 and 300+ clients and partners all around the world.
We are a CRO specialising in the analysis of proteins and their associated PTM’s via advanced Mass Spectrometry. By using proprietary methodologies, we can detect up to 8,000 proteins per sample in Discovery mode and can offer multiplexed assays of up to 100 proteins/sample in a GCLP accredited Targeted assay.
With their proprietary bioinformatics software, these can be trimmed down to some tens of proteins that are either up-, or down-regulated with disease progression or drug treatment.
Established in 2004, LARVOL combines the best of artificial and human intelligence to deliver expertly curated and personalized data solutions to medical affairs, competitive intelligence, commercial, and R&D teams within the pharmaceutical and biotech industry.
With over 15 years of experience in genetic and epigenetic clinical research, EpigenDx offers high quality products and laboratory services focused on DNA methylation analysis, gene expression profiling, and mutation analysis. Our scientific teams carefully evaluate each project and establish analysis procedures using best fit technologies, including NGS, Pyrosequencing, RT-PCR, digital PCR, and GeneChip Microarray. Our popular services include Line-1 global methylation tests and Foxp3-TSDR analysis for epigenetic immunotherapy. Our GLP compliant and CLIA certified services make us the perfect partner during pre-clinical research and diagnostic test development.
Veracyte is a pioneering, global diagnostics company that improves patient care by answering important clinical questions to inform diagnosis and treatment decisions. Our growing menu of advanced diagnostic tests help patients avoid risky, costly procedures and interventions, and accelerate time to appropriate treatment. Veracyte offers customized multi-omics tools and expertise to our biopharmaceutical partners, helping them advance their therapeutic discovery, development and commercialization programs.
Based on the fully human antibody transgenic RenMab™, RenLite™, and RenNano™ Mice, Biocytogen has integrated its technology platforms in single-cell antibody discovery, gene editing, large-scale disease mouse model supply, and in vivo pharmacology screening to form a new approach to streamline the entire antibody drug discovery and development process. Biocytogen collaborates with global partners to accelerate new drug discovery and development. For more information, please visit www.biocytogen.com
BostonGene’s mission is to power healthcare’s transition to personalized medicine using AI-based molecular and immune profiling to improve the standard of care, accelerate research, and reduce overall cost of cancer care. BostonGene’s tests reveal key drivers of each tumor, including immune microenvironment properties, actionable mutations, biomarkers of response to diverse therapies, and recommended therapies. Through these comprehensive analyses, BostonGene’s tests generate a personalized roadmap for therapeutic decision-making for each cancer patient.
TransCure bioServices (TCS) provides predictive in vivo pharmacology expertise for drug pre-clinical candidate selection in the fields of infectious, cancer (IO, PDX), inflammation, vaccine and immune disease areas. We are the only preclinical CRO providing commercially HIV, immuno-oncology (IO) therapy, PDX, IBD, vaccine and autoimmune mouse models with a fully functional reconstituted HUMAN IMMUNE SYSTEM (hu-mouse models). We co-design study protocols/experiments performing the ordered studies and providing comprehensive data collection, data analysis and reports.
Every day, QIAGEN serves 500,000 customers globally, all seeking insights from DNA and RNA. Delivering Sample to Insight solutions for molecular testing, we help scientists and clinicians achieve breakthroughs in life sciences research, molecular diagnostics and drug development. This is how we make improvements in life possible. In healthcare and academic institutions, and drug-discovery and forensic laboratories, QIAGEN solutions advance disease detection and treatments, enable precision medicine, and aid crime detection and human identification.
Q2 Solutions is a leading global clinical trial laboratory services organization with end-to-end laboratory services and secure, enterprise-wide biospecimen and consent management solutions. Q2 Solutions uses global experience, innovation and scientific expertise to transform science and data into medical insights that turn hope into help. A joint venture of IQVIA and Quest Diagnostics, Q2 Solutions leverages each parent organization’s clinical trials laboratory capabilities and treats each sample as if a life depends on it.
Cureline, Inc. is a global contract research organization (CRO) and a commercial biobank supporting preclinical research in oncology, hematology, immune-oncology and various other therapeutic areas (Cardio-vascular, metabolic, neuro-degenerative, infectious and inherited conditions) to the pharmaceutical, biotechnology, and medical device industries worldwide since 2003.
Biointron is a leading high throughput recombinant antibody/protein expression provider. From gene sequence to purified antibodies, it just takes 2 weeks. Till now, Biointron has delivered tens of thousands of recombinant antibodies/proteins for nearly 1,000 biotech/biopharma companies all over the world. Biointron has various platforms for antibody discovery, including single B screening, phage display, we are offering antibody humanization & affinity maturation,VHH antibody (from Alpacas) development and a lot of in-vitro assays. Also, Biointron licensed CHO-K1 cell line from ECACC and got the sub-licence authorization, can provide high-yield guaranteed (>5 g/L for antibody) and speedy timeline stable cell line service. Besides customized services, Biointron offer a comprehensive portfolio of catalog products, including research grade biosimilar antibodies, isotype control antibodies. All these catalogue products are subject to strict experimental verification and quality control.
StackWave is a software solutions provider that is focused exclusively on biologics discovery. We provide the industry’s most complete, integrated, antibody discovery informatics platform. Our holistic approach allows us to seamlessly integrate your discovery operations, from early discovery and lead identification to in-depth characterization. StackWave Affinity™ is a cloud-ready software application that provides support for in-vitro and in-vivo discovery; clone plate generation, screening, and sequencing; cloning, reformatting, and expression; inventory management; and characterization and reporting.
Headquartered in Tucson, Arizona, HTG is focused on accelerating precision medicine – from diagnosis to treatment – by harnessing the power of transcriptome-wide profiling to drive translational research, clinical diagnostics and targeted therapeutics across a variety of disease areas. HTG’s proprietary extraction-free RNA expression technology simplifies and automates complex, highly multiplexed gene expression profiling from solid and (biofluid) liquid samples, even when limited by amount and quality. HTG’s transcriptome and targeted panels are designed to enable biomarker profile assessment and gene signature development associated with disease state, treatment response and outcome.
Concept Life Sciences is a knowledge-based, science-led and customer-focused contract research and manufacturing organisation with world-leading expertise in the pharmaceutical, biotech and agrochemical industries. We are based across 5 sites in the UK delivering discovery research as well as GMP, GLP and GCP-regulated work. Whether it is delivering whole programs of research or bespoke studies we deliver a collaborative client-centred approach. Our services are built on scientist-to-scientist engagement, deep knowledge, flexibility and extensive in-house resources. Our services span and can scale to every stage from discovery to development:
Detai Bioscience, Inc. ("DetaiBio"), established in 2013, is a CRO vendor focusing on antibody discovery and functional protein research field. DetaiBio is aiming to provide high quality and economic service to speed up life science for our client in different fields, such as antibody drug discovery, in-vitro diagnosis and academic research.
Talem Therapeutics is a biotherapeutic company and a wholly owned subsidiary of ImmunoPrecise Antibodies (IPA) that leverages IPA’s antibody discovery and development expertise combined with AI/bioinformatics to generate valuable assets (best-in-class / first-in-class) for out-licensing and co-development. Talem's experts focus on next generation antibodies from target validation through IND-Readiness (indication agnostic).